Cargando…
Cardiac fibrosis can be attenuated by blocking the activity of transglutaminase 2 using a selective small-molecule inhibitor
Cardiac fibrosis is implicit in all forms of heart disease but there are no effective treatments. In this report, we investigate the role of the multi-functional enzyme Transglutaminase 2 (TG2) in cardiac fibrosis and assess its potential as a therapeutic target. Here we describe the use a highly se...
Autores principales: | Wang, Zhuo, Stuckey, Daniel J., Murdoch, Colin E., Camelliti, Patrizia, Lip, Gregory Y. H., Griffin, Martin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5966415/ https://www.ncbi.nlm.nih.gov/pubmed/29795262 http://dx.doi.org/10.1038/s41419-018-0573-2 |
Ejemplares similares
-
Transglutaminase 2: a novel therapeutic target for idiopathic pulmonary fibrosis using selective small molecule inhibitors
por: Fell, Shaun, et al.
Publicado: (2021) -
Small Molecule Inhibitors Target the Tissue Transglutaminase and Fibronectin Interaction
por: Yakubov, Bakhtiyor, et al.
Publicado: (2014) -
In vivo MRI Characterization of Progressive Cardiac Dysfunction in the mdx Mouse Model of Muscular Dystrophy
por: Stuckey, Daniel J., et al.
Publicado: (2012) -
Transglutaminase-2: Nature’s Glue in Lung Fibrosis?
por: Sanders, Yan Y., et al.
Publicado: (2021) -
Biochemical and Functional Characterization of the Three Zebrafish Transglutaminases 2
por: Lisetto, Manuel, et al.
Publicado: (2023)